YieldMax DIS期權收益策略主動型ETF DISO 深 滬
交易中 05-18 11:40:13 美东时间
9.96
+0.155
+1.58%
華盛通- 最 高9.96
- 今 開9.805
- 成交量 907股
- 最 低 9.88
- 昨 收 9.805
- 總市值 498.00万
- 52周最高 11.4427
- 市盈率 靜 --
- 換手率 0.18%
- 52周最低 9.0662
- 委 比 42.86%
- 總股本 50.00万
- 歷史最高 12.0795
- 量 比 0.57
- 振 幅 0.82%
- 歷史最低 5.6293
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Italy - Factors to watch on May 7
Italy - Factors to watch on May 7 The following factors could affect Italian markets on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS U.S. Se
05-07 12:00
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders
BRIEF-Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders Clearmind Medicine Inc CMND.O : CLEARMIND MEDICINE FILES PATENT APPLICATION IN INDIA FOR NEXT-GEN PSYCHEDELIC COMPOUNDS TO TREAT MENTAL HEALTH DISORDERS Source text: ID:nGNX
03-27 19:45
BRIEF-Oryzon Gets US Patent Allowance For Vafidemstat
BRIEF-Oryzon Gets US Patent Allowance For Vafidemstat March 25 (Reuters) - Oryzon Genomics SA ORY.MC : STRENGTHENS VAFIDEMSTAT PATENT PORTFOLIO WITH U.S. NOTICE OF ALLOWANCE U.S. PATENT EXPECTED TO REMAIN IN FORCE UNTIL AT LEAST 2040, EXCLUDING ANY POTENTIAL PATENT TERM ADJUSTMENTS OR EXTENSIONS PAT
03-25 14:29
BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital
BRIEF-Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital March 16 (Reuters) - Alzamend Neuro Inc ALZN.O : ALZAMEND NEURO INITIATES PHASE II CLINICAL TRIAL OF AL001 "LITHIUM IN BRAIN
03-16 20:17
BRIEF-Vanda Announces FDA Grants Landmark Hearing For Hetlioz® In Jet Lag Disorder, The First Drug Approval Hearing In Over 40 Years
BRIEF-Vanda Announces FDA Grants Landmark Hearing For Hetlioz® In Jet Lag Disorder, The First Drug Approval Hearing In Over 40 Years March 3 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O : VANDA ANNOUNCES FDA GRANTS LANDMARK HEARING FOR HETLIOZ® IN JET LAG DISORDER, THE FIRST DRUG APPROVAL HEARING IN
03-03 21:11
BRIEF-Con Edison Announces Common Share Offering With A Forward Component
BRIEF-Con Edison Announces Common Share Offering With A Forward Component Feb 23 (Reuters) - Consolidated Edison Inc ED.N : CON EDISON ANNOUNCES COMMON SHARE OFFERING WITH A FORWARD COMPONENT CONSOLIDATED EDISON INC - PUBLIC OFFERING OF 7 MILLION COMMON SHARES CONSOLIDATED EDISON INC - PROCEEDS TO
02-24 05:58
LIVE MARKETS-UBS downgrades communication services, upgrades industrials
LIVE MARKETS-UBS downgrades communication services, upgrades industrials Main US indexes red; Dow down most, off ~0.6% Financials weakest S&P 500 sector; Utilities leads gainers Dollar up; gold up slightly; bitcoin up >1%; crude rallies >2% US 10-Year Treasury yield edges down to ~4.07% Welcome to t
02-20 03:09
LIVE MARKETS-Potential US-Iran conflict may be completely underpriced
LIVE MARKETS-Potential US-Iran conflict may be completely underpriced Main US indexes red; Dow down most, off ~0.6% Financials weakest S&P 500 sector; Energy leads gainers Euro STOXX 600 index down ~0.6% Dollar, gold rise; crude rallies >2%; bitcoin ~flat US 10-Year Treasury yield edges up to ~4.08%
02-20 01:15
LIVE MARKETS-Disobedient data: Jobless claims dip, goods trade gap hits record, pending home sales slip
LIVE MARKETS-Disobedient data: Jobless claims dip, goods trade gap hits record, pending home sales slip US stocks modestly lower Financials weakest S&P 500 sector; Energy leads gainers Euro STOXX 600 index down ~0.6% Dollar, bitcoin, gold gain; crude up >2% US 10-Year Treasury yield edges up to ~4.0
02-20 00:42
Italy - Factors to watch on February 17
Italy - Factors to watch on February 17 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . ECONOMY IST
02-17 13:00
